Form 4: Director Rimma Driscoll Receives DexCom RSU Grant
Director Equity Compensation Disclosure
DexCom Director Rimma Driscoll was granted 5,605 restricted stock units as part of her annual equity compensation.
Summary
- Director Rimma Driscoll acquired 5,605 restricted stock units (RSUs) on May 28, 2026.
- The RSUs represent a contingent right to receive one share of DexCom common stock per unit upon settlement.
- The award is scheduled to vest on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting of Stockholders.
- Following this transaction, the director's total beneficial ownership stands at 17,319 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.
Positives
- The grant aligns the director's interests with long-term shareholder value through equity-based compensation.
Negatives
- None identified; this is a standard equity compensation disclosure.
Risks
- The value of the equity grant is subject to market volatility and the future performance of DexCom common stock.
Future Outlook
The RSU award is subject to vesting conditions tied to the one-year anniversary of the grant or the 2027 Annual Meeting of Stockholders.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard corporate governance practices designed to ensure director alignment with shareholder interests in the medical technology sector.
Comparison to Industry Standards
- The use of RSUs for director compensation is consistent with standard practices among S&P 500 and mid-cap healthcare technology companies.
- Vesting schedules tied to annual meetings are common practice for board-level equity awards.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Rimma Driscoll appointed Jereme Sylvain, Christophe Cantenot, and Stephanie Fong as attorneys-in-fact for SEC filings. | 2025-05-28 | Standard administrative procedure to facilitate timely regulatory reporting. |
Stakeholder Impact
- Minimal impact on shareholders as this is a standard compensation event.
Next Steps
- Vesting of 1,336 RSUs on August 24, 2026.
- Vesting of 5,605 RSUs on or before the 2027 Annual Meeting of Stockholders.
Key Dates
| Date | Description |
|---|---|
| 2023-08-24 | Grant date of previous RSU award. |
| 2026-05-28 | Grant date of new RSU award and date of earliest transaction. |
| 2026-06-01 | Date of filing signature. |
| 2026-08-24 | Vesting completion date for previous RSU award. |
| 2027-05-28 | Expected vesting date for the new RSU award. |
Keywords
DexCom, DXCM, Director Compensation, Insider Transaction, Restricted Stock Units, Equity Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.